MADISON, Wis., May 21, 2021 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS) today highlights data from one oral and one poster presentation being featured at the 2021 Digestive Disease Week® (DDW® ...

Note: specificity including non-advanced findings includes colonoscopy results that were negative for cancer or advanced precancer upon histopathological review; specificity including no findings ...

Cologuard Plus, a new version of the Cologuard colorectal screening test, became available in 2025. The manufacturer says the upgraded test may be 30% more accurate than the original Cologuard. If you ...

MADISON, Wis., Oct. 22, 2023 /PRNewswire/ -- Exact Sciences Corp. (EXAS), a leading provider of cancer screening and diagnostic tests, today announced late-breaking data from the pivotal BLUE-C trial ...

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced an expanded partnership with Humana Inc. to enhance ...

A colonoscopy is recommended every decade for people over 45. The screening is used to detect colon cancer. But roughly 40% of eligible Americans don't get a colonoscopy, often because they don't want ...

Jeff Smith was dumbfounded when he received a colon cancer screening kit in the mail. The 68-year-old Minnesota man hadn't asked for the Cologuard test, and his doctor hadn't mentioned anything about ...

Exact Sciences completed 1.69 million Cologuard tests in 2019, and while the test was found to have 92 percent sensitivity and 87 percent specificity rates for detecting colorectal cancer, it remains ...

American College of Gastroenterology (ACG) gives BLUE-C study late breaker status at 2023 annual meeting with presentation of the only head-to-head study results versus FIT at ACG High specificity for ...